Merck & Co. is paying $10.8 billion to buy Prometheus Biosciences for its late-phase bowel disease drug candidate. Months after midphase data sent Prometheus’ stock spiraling upward, Merck has agreed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback